Cancer Family
Esophageal Neoplasm
CI-CAN-00000174Explore in graph →
Non-malignant555 active trials6 approved drugs12 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000174Explore in graph →
Clinical trials
2,208 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03958890 | A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 3 | 489 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05817201 | Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy | unknown | Phase 2 / Phase 3 | 60 | Taizhou HospitalOTHER | 1 | Apr 18, 2023 |
| clinicaltrials |
| NCT03908671 | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer | unknown | N/A | 24 | Stemirna TherapeuticsINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04389177 | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05690958 | Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening(ACCEPT-survey) | unknown | — | 2,088 | Radboud University Medical CenterOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05791136 | Immunotherapy After Radiotherapy in Elderly ESCC(TREE) | unknown | Phase 2 | 30 | The Central Hospital of Lishui CityOTHER | 0 | Mar 30, 2023 | clinicaltrials |
| NCT05789498 | Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients | unknown | — | 60 | Zhao JunOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05777707 | Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma | unknown | Phase 1 / Phase 2 | 89 | Beijing Friendship HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05633342 | Project CADENCE (CAncer Detected Early caN be CurEd)(CADENCE) | unknown | — | 15,000 | MiRXES Pte LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05768282 | Oral Prednisolone to Prevent Esophageal Stricture After RFA for Long-segment Esophageal Neoplasia | unknown | Phase 4 | 50 | E-DA HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05323890 | Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma. | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05192460 | Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer | unknown | N/A | 30 | jianming xuOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT05163483 | Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer | unknown | Phase 2 | 87 | Ruihua XuOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04673968 | Prehabilitation on Fitness, Surgical Outcomes and Mitochondria Functionality in Patients With Esophageal Cancer | unknown | N/A | 160 | Chang Gung Memorial HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05725473 | Clinical Efficacy and Safety of Endoscopic Dilatation With Eso-Filp in Benign Esophageal Strictures(ESO-FLIP) | unknown | N/A | 15 | Istituto Clinico HumanitasOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02025036 | Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer(CRTCOESC) | unknown | Phase 3 | 249 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04425122 | The Microbiome of Oesophageal Squamous Cell Carcinoma | unknown | — | 200 | Chinese University of Hong KongOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05685862 | Laser Speckle Contrast Imaging, Surgical Eye & ICG Fluorescence Imaging for Perfusion Assessment of the Gastric Conduit(CONDOR-I) | unknown | — | 30 | Frisius Medisch CentrumOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT04489368 | Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning(QARC) | unknown | — | 150 | Dr Kundan Singh ChufalOTHER | 2 | Dec 28, 2022 | clinicaltrials |
| NCT05662644 | Assessment of Minimally Invasive Surgery for Esophageal Cancer | unknown | N/A | 30 | Sohag UniversityOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05210049 | Non-endoscopic Esophageal Sampling to Detect Barrett's Esophagus and Esophageal Cancer in Veterans | unknown | N/A | 125 | Louis Stokes VA Medical CenterFED | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05650216 | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC(NICE-RT) | unknown | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05636150 | A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 48 | Peking Union Medical College HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05637268 | Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 23 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05633641 | Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma | unknown | — | 60 | Fudan UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05615103 | The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer(POSITRON) | unknown | — | 100 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05386056 | Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 54 | Peking UniversityOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05596890 | Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients(PICCRT) | unknown | Phase 2 | 50 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05626309 | Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer | unknown | N/A | 310 | Jie LiOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05303298 | Evaluating Acid Reflux After Oesophageal Stenting Using Anti-reflux Stents | unknown | N/A | 72 | University of Cape TownOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05594914 | AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 47 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Oct 26, 2022 | clinicaltrials |
| NCT05570487 | RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY | unknown | — | 1,600 | Yongtao HanOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05561699 | Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer(SPEED) | unknown | N/A | 66 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03990532 | Simultaneous Integrated Boost for Mediastinal Lymph Node Recurrence After Radical Surgery of Esophageal Cancer | unknown | N/A | 46 | Ruijin HospitalOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05552651 | Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tao JiangOTHER | 0 | Sep 23, 2022 | clinicaltrials |
| NCT05543057 | Real-world Study on Comprehensive Treatment of Esophageal Cancer Based on Precision Radiotherapy | unknown | — | 150 | Zefen XiaoUNKNOWN | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05425472 | A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer | unknown | Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05522894 | AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC | unknown | Phase 2 | 80 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 31, 2022 | clinicaltrials |
| NCT04699994 | Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel | unknown | Phase 2 | 60 | Keio UniversityOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05170256 | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients(HERES) | unknown | Phase 2 | 24 | Morten Mau-SørensenOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05498168 | Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens | unknown | — | 50 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05476380 | Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05469061 | Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC | unknown | Phase 2 | 17 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03946969 | Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05460403 | Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection | unknown | — | 3,591 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05174156 | Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer | unknown | Phase 2 | 50 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT05449483 | Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05424432 | Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus(SCALE-2) | unknown | Phase 2 | 63 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jun 27, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 18, 2023source: clinicaltrials